DiaMedica Therapeutics is a clinical-stage biopharmaceutical company committed to changing the treatment paradigm for acute ischemic stroke (AIS) and preeclampsia (PE). Our initial product candidate, DM199, mimics the behavior of naturally-occurring human tissue kallikrein-1 (KLK1) proteins to increase collateral circulation in stroke-affected tissue and improve blood pressure control and overall endothelial health.
We believe that DM199 (rhKLK1) has the potential to treat multiple diseases. By restoring levels of the naturally occurring protein KLK1, DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. Our research is focused on exploring this potential in acute ischemic stroke, preeclampsia and other diseases where promoting homeostasis and improving blood flow throughout the body is beneficial.
We have developed a pharmacologically active recombinant form of KLK1. DM199 (rhKLK1) represents an optimized, patent-protected formulation combining closely related isoforms with varying degrees of glycosylation, a critical component of the candidate's effectiveness.
We have licensed a proprietary cell line technology that efficiently and reliably produces large amounts of KLK1. The patent-protected manufacturing process covers all the vectors and reagents used to manufacture DM199 at scale.
Our composition of matter and delivery patents are protected until 2033. Worldwide dose, route of delivery, formulation and indication patents provide coverage to 2038.
